$16.07
+0.25 (+1.58%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ANGO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
18 interventional · 4 observational · 5 with posted results
Held by 11 tracked-famous managers (Point72 Asset Management, L.P., MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, AQR CAPITAL MANAGEMENT LLC, MARSHALL WACE, LLP, +6 more) · FINRA short interest 2.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Auryon Atherectomy System With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone in EuropeNCT07472439Win-ratio comparing subjects in the treatment group versus the control group on the components of the composite endpoints in a hierarchical fashion at 12 monthsRandomized · Open-label · Treatment | Not applicable | Not yet recruiting | Device: Auryon Atherectomy System, Balloon Angioplasty | Peripheral Arterial Disease | 50 | May 2029 | ≤ 1,015 d | 2026-03-16 |
| Auryon Atherectomy System With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty AloneNCT06777901Win-ratio comparing subjects in the treatment group versus the control group on the components of the composite endpoints in a hierarchical fashion at 12 monthsRandomized · Open-label · Treatment | Phase 4 | Recruiting | Device: Auryon Atherectomy System, Balloon Angioplasty | Peripheral Arterial Diseases | 224 | Feb 2029 | ≤ 923 d | 2026-01-08 |
| Evaluating the Efficacy, Safety and Long Term Functional Outcomes of Percutaneous Mechanical Aspiration Thrombectomy for Treatment of Acute Pulmonary Embolism Using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 SystemNCT06697314Reduction in RV/LV ratioOpen-label · Treatment | Not applicable | Recruiting | Device: AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System | Acute Pulmonary Embolism (PE), Pulmonary Embolism | 256 | Jun 2028 | ≤ 680 d | 2025-09-26 |
| International Study on Treatment of Patients With Metastatic Colorectal Liver Lesions Patients With IRENCT07191548Target Tumour EradicationOpen-label · Treatment | Not applicable | Not yet recruiting | Device: Irreversible Electroporation | Colorectal Adenocarcinoma Metastatic in the Liver, Liver Ablation, Liver Cancer, Adult | 50 | Feb 2028 | ≤ 558 d | 2025-10-10 |
| International Study on Treatment of Liver (HCC) Patients With IRENCT07192731Target Tumour EradicationOpen-label · Treatment | Not applicable | Not yet recruiting | Device: Irreversible Electroporation | Hepatocellular Carcinoma (HCC), Liver Ablation, Liver Cancer, Adult | 50 | Feb 2028 | ≤ 558 d | 2025-10-10 |
| Irreversible Electroporation (IRE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)NCT07640776Incidence and severity of device-related adverse events (AEs) through 6 months post-procedureOpen-label · Treatment | Not applicable | Not yet recruiting | Device: Irreversible Electroporation | Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH) | 40 | Dec 2027 | ≤ 498 d | 2026-06-11 |
| Acute Pulmonary Embolism Treatment With the AlphaVac Multipurpose Mechanical Aspiration System and the AlphaReturn Blood Management System: Evaluation of Safety and EffectivenessNCT07280247Rate of Device-Related Adverse Events (AEs)Open-label · Treatment | Not applicable | Recruiting | Device: AlphaReturn Blood Management System | Pulmonary Embolism Acute | 39 | Dec 2026 | ≤ 133 d | 2026-05-11 |
| Percutaneous AngioVac Vegetation Extraction (PAVE) to Remove Right Heart Vegetations in Patients With Infective EndocarditisNCT07282002Rate of Clinical SuccessOpen-label · Treatment | Not applicable | Not yet recruiting | Device: AngioVac System | Infective Endocarditis (IE) | 30 | Nov 2026 | ≤ 102 d | 2026-04-22 |
| A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic CancerNCT03899636Overall SurvivalRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Modified FOLFIRINOX Regimen · Device: NanoKnife System | Stage III Pancreatic Cancer | 528 | Apr 2025 | — | 2025-02-12 |
| A Registry Study of NanoKnife IRE for Stage 3 Pancreatic CancerNCT03899649observationalOverall Survival | — | Active, not recruiting | Drug: SOC · Device: NanoKnife System | Stage III Pancreatic Cancer | 532 | Apr 2025 | — | 2025-02-12 |
| Pivotal Study of the NanoKnife System for the Ablation of Prostate TissueNCT04972097results2026-06-02Number of Participants With a Negative In-field Biopsy at 12 MonthsOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Irreversible Electroporation | Prostate Cancer | 121 | 2024-08-14actual | — | 2026-06-02 |
| Evaluating the Safety and Efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for Treatment of Acute Pulmonary EmbolismNCT05318092results2024-07-19Change in Right Ventricle to Left Ventricle (RV/LV) Ratio Between Baseline and 48 Hours Post-procedure Assessed by Computed Tomography Angiography (CTA)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE | Pulmonary Embolism, Acute Pulmonary Embolism | 122 | 2024-01-04actual | — | 2024-07-19 |
| Study of NanoKnife for Ablation of Prostate Cancer in Intermediate Risk PatientsNCT01972867Treatment procedural and short-term post-treatment safety profileOpen-label · Treatment | Not applicable | Unknown status | Device: NanoKnife Procedure | Prostate Cancer | 6 | 2022-11-01actual | — | 2023-02-01 |
| Post-Market Registry of AURYON Atherectomy Device in Subjects Affected With Infrainguinal Peripheral Artery DiseaseNCT04229563results2026-05-18observationalPrimary Efficacy: Acute Procedural SuccessStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Device: AURYON Atherectomy System | Infrainguinal Peripheral Artery Disease, Peripheral Arterial Disease, PAD | 102 | 2021-03-17actual | — | 2026-05-18 |
| SeCure Endovenous Laser Treatment StudyNCT02215369results2020-04-21Acute Primary Ablation SuccessOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: VenaCure EVLT 400 µm fiber Procedure Kit | Chronic Venous Insufficiency | 112 | Mar 2018actual | — | 2020-05-19 |
| Initial Experience With the AngioVac Venous Drainage CannulaNCT02775565observationalDetailing early clinical experience with the AngioVac Venous Drainage Cannula | — | Completed | Device: AngioVac | Heart Disease | 51 | Sep 2016actual | — | 2017-12-08 |
| The PROOF Study: The PICC Related Obstruction Of Flow StudyNCT01921114results2019-05-17Incidence of Catheter-related Venous Thrombosis as Confirmed by Diagnostic UltrasoundRandomized · Single-masked · Treatment | Not applicable | Terminatedsponsor's stated reason: Low enrollment | Device: BioFlo™ Peripherally Inserted Central Catheter (PICC), Bard® Dual-Lumen PowerPICC SOLO2® | Patients Indicated for a PICC for Any Medical Condition | 57 | Jul 2014actual | — | 2019-05-17 |
| Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC)NCT01078415Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.Open-label · Treatment | Not applicable | Completed | Device: Ablation with the NanoKnife Low Energy Direct Current (LEDC) System | Carcinoma, Hepatocellular | 26 | Jan 2013actual | — | 2016-11-08 |
| Post-Market Observation Study of Intra-renal Drug Delivery (PROVIDE)NCT01064895observational | — | Terminated | Device: Benephit catheter for Targeted Renal Therapy | Acute Kidney Injury, Acute Renal Failure, Renal Failure Chronic Contrast Induced, Chronic Kidney Disease | — | Dec 2011actual | — | 2016-11-08 |
| NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic CancerNCT01369420SafetyOpen-label · Treatment | Phase 2 | Completed | Device: NanoKnife Low Energy Direct Current (LEDC) System Ablation | Pancreatic Adenocarcinoma | 10 | Dec 2011actual | — | 2016-11-08 |
| Comparison Study for Safety and Efficacy of Two Devices for the Treatment of the Great Saphenous VeinNCT01173419Incidence of post operative adverse events/ effects between the two treatment groups.Randomized · Single-masked · Treatment | Not applicable | Withdrawnsponsor's stated reason: Business decision to reevaluate clinical needs. | Device: VNUS RF ClosureFAST, VenaCure EVLT NeverTouch | Varicose Veins, Venous Insufficiency | 0 | Feb 2011 | — | 2012-07-13 |
| Radiofrequency Ablation of Pulmonary Tumors Response EvaluationNCT00690703technical successOpen-label · Treatment | Phase 2 | Completed | Device: RF ablation (Rita Medical Systems Model 1500x) | Non Small Cell Lung Cancer, Pulmonary Metastases | 106 | Dec 2006actual | — | 2008-06-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19